← Back to Search

[11C]MK-3168 for Post-Traumatic Stress Disorder

Phase < 1
Waitlist Available
Led By Mohini Ranganathan, MBBS
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pet scan day
Awards & highlights
No Placebo-Only Group

Summary

This trial looks at the effects of FAAH in humans with psychiatric disorders.

Eligible Conditions
  • Post-Traumatic Stress Disorder
  • Alcoholism
  • Psychosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pet scan day
This trial's timeline: 3 weeks for screening, Varies for treatment, and pet scan day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Total distribution of [11C]MK-3168 in the brain

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [11C]MK-3168 PET ScanExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[11C]MK-3168
2021
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,913 Previous Clinical Trials
3,039,476 Total Patients Enrolled
Mohini Ranganathan, MBBSPrincipal InvestigatorNeuroscience Research Training Program (NRTP); Office of Cooperative Research; Psychiatry; Schizophrenia Research Clinic; Yale University
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top